Cargando…
Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET). T...
Autores principales: | Suyama, Koichi, Iwase, Hirotaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/ https://www.ncbi.nlm.nih.gov/pubmed/30032643 http://dx.doi.org/10.1177/1073274818789361 |
Ejemplares similares
-
Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017) -
Savolitinib: A Promising Targeting Agent for Cancer
por: Lee, Tae Seung, et al.
Publicado: (2023) -
Lenvatinib plus pembrolizumab a new effective combination of targeted agents
por: Perez-Fidalgo, J.A., et al.
Publicado: (2023) -
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022) -
The Promise of Integrins as Effective Targets for Anticancer Agents
por: Rust, William L., et al.
Publicado: (2002)